What the business is, and whether it's a good one at a fair price.
Operates a network of 68 diagnostic centres providing pathology and radiology testing services, primarily in West Bengal with newer hubs in Bihar, Tripura, Jharkhand and Assam. In FY26, the network served 1.37 million patients and conducted 8.16 million tests, generating revenue per patient of INR 2,264. The revenue mix is 49% pathology, 44% radiology and 7% integrated doctor consultancy, close to the industry-wide ~55:45 pathology-to-radiology split. Mature centres (over 2 years old) generate 36-37% EBITDA margins while newer centres are at -5.5% during ramp-up, blending to an FY26 EBITDA margin of 31.75%. A genomics vertical (Suraksha Genomics) has been launched using the Genexus NGS platform for 48-72 hour oncology turnaround, running at INR 35 lakh/month, and a 63% stake in fertility chain Fetomat Wellness was acquired in April 2025. Employee costs (17.2% of revenue) and other operating expenses (40.4% of revenue) are the largest cost lines, with capex at 21.7% of revenue supporting the hub-and-spoke rollout toward 100 centres by FY28.
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SURAKSHA DIAGNOSTIC LTD's filed financials and exchange disclosures
SURAKSHA DIAGNOSTIC LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol SURAKSHA.
Yes. Over the trailing twelve months SURAKSHA DIAGNOSTIC LTD reported a net profit of ₹35 Cr on revenue of ₹325 Cr.
Not in the latest reported year — SURAKSHA DIAGNOSTIC LTD's dividend payout for FY26 was nil.
Effectively yes. It holds ₹1 Cr more cash than debt. Debt stands at 0.01× equity.
On trailing P/E, SURAKSHA DIAGNOSTIC LTD ranks 21 of 29 in Healthcare Service Provider — cheaper than 29% of them, against an industry median of 23.2×. This is a position, not a valuation judgement.
On a typical session SURAKSHA DIAGNOSTIC LTD moves 1.02% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SURAKSHA DIAGNOSTIC LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
